Cosyntropin
Acth
Sold as Cortrosyn · SYNACTHEN DEPOT
- Drug class
- Acth
- Availability
- Prescription only
- Routes
- Intramuscular, Intravenous, Parenteral
- Markets covered
- 3
- Products on record
- 9
- FDA reports (12 mo)
- 16
Overview
Plain-language summary, compiled from the cited regulatory records
Cosyntropin is a medication classified as an adrenocorticotropin hormone [1]. It is approved for use as a diagnostic agent, in conjunction with other diagnostic tests, to screen for adrenocortical insufficiency in both adult and pediatric patients [1]. This condition affects the adrenal glands' ability to produce necessary hormones.
In the market, cosyntropin is available under brand names such as Cortrosyn [1]. In the past 12 months, there have been 16 adverse event reports associated with cosyntropin [2]. The most frequent reactions noted in these reports include decreased anticonvulsant drug levels, drug interactions, hypertension, rash, and supraventricular tachycardia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 4 | June 17, 2025 |
| GB United Kingdom | MHRA | 4 | May 22, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
USUnited States· FDA
4 products
Uses
1 Indications and Usage CORTROSYN is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. CORTROSYN is an adrenocorticotropin hormone indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients.
(1)
How to take
GBUnited Kingdom· MHRA
4 products
Uses
Diagnostic test for the investigation of adrenocortical insufficiency.
How to take
CACanada· Health Canada
1 product
Uses
11 CLINICAL TRIALS .......................................................... Error! Bookmark not defined. V. 25 mg/ vial Mannitol and water for injection May contain glacial acetic acid and sodium hydroxide for pH adjustment. 25 mg) is indicated for: • use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
Because of the possibility of an allergic reaction, the injection should be given under medical supervision and the patient kept under observation for about an hour. Self injection by patients is not recommended. Because of its rapid effect on the adrenal cortex, it is now possible to perform a 30 minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure using only 2 venipunctures.
(See DOSAGE AND ADMINISTRATION) Geriatrics (> 65 years of age): No data is available.
Pediatrics (< 16 years of age):
Drug interactions
Known interactions involving Cosyntropin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0c424fac-b114-41… · revised June 17, 2025 [PDF]
- [2]MHRA (UK) · PL432520026 · revised August 15, 2025
- [3]Health Canada (DPD) · 00022381 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.